Open Access Repository

Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review

Kefale, AT, Peterson, GM ORCID: 0000-0002-6764-3882, Bezabhe, WM ORCID: 0000-0002-3028-6949 and Bereznicki, LR ORCID: 0000-0003-3974-3437 2021 , 'Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review' , British Journal of Clinical Pharmacology , pp. 1-20 , doi: 10.1111/bcp.15021.

Full text not available from this repository.


Approval of direct-acting oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF) was an important milestone, providing a wider range of treatment options and creating the possibility for drug switching after initiation. In addition to improved utilisation of oral anticoagulants (OACs) for stroke prevention, reports of switching among OACs are growing in the literature; switching may influence clinical outcomes, healthcare costs and patient satisfaction. This review aimed to summarise the current literature on the pattern of OAC switching in patients with AF, including reasons for switching and clinical consequences following switching. A literature search was conducted in PubMed, Scopus and Embase on 27 June 2020. We included 39 articles published after 2013, following the introduction of apixaban. The review found that switching among OACs was common in clinical practice, significantly varying with the type of OAC. Studies reporting the reason for switching and clinical outcomes were comparatively limited. The decision to switch was often related to safety issues (usually bleeding), poor anticoagulation control and ease of use. Patient characteristics, clinical conditions and drug interactions were found to be associated with switching from OACs. Findings regarding bleeding outcomes following switching were inconsistent, possibly confounded by the rationale for switching and the switching protocol. Noting the limited number of studies included and their relatively short follow-up periods, switching did not have a significant impact on the risk of stroke and other thrombotic outcomes. Further prospective studies are needed to understand better potential rationales for switching and the clinical outcomes.

Item Type: Article
Authors/Creators:Kefale, AT and Peterson, GM and Bezabhe, WM and Bereznicki, LR
Keywords: atrial fibrillation, direct-acting oral anticoagulants, switching, warfarin, primary care
Journal or Publication Title: British Journal of Clinical Pharmacology
Publisher: Blackwell Publishing Ltd
ISSN: 0306-5251
DOI / ID Number: 10.1111/bcp.15021
Copyright Information:

© 2021 British Pharmacological Society

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page